Young man, 21 years of age. type 1 diabetes since 9 years of age. Has not been to see hcp for a year. States he doesn’t like people interrogating him, but came in because he needs his insulin. States he doesn’t check his glucose because he can tell what it is. Tired of having type 1 diabetes and tired of checking numbers. A1C in office--10.2%.
Read More »The Insulin Pump Market: A Look Back at 2017 and Ahead to the New Year
By Guest Writer David Kliff, Publisher, Diabetic Investor
As 2018 begins, my attention turns toward a look back at the year gone by and ahead to the year that’s starting. As always, my New Year will begin in that beautiful city by the bay at the JP Morgan Healthcare Conference. This is a conference I suspect will be one of the more interesting, and since I’ve attended nearly 20, that’s saying something. Lots is going on behind the scenes in our wacky world, and given the nature of JPM I suspect the veil of secrecy will be lifted.
Why Data-Driven Diabetes Management Systems are the Future
By Guest Writer David Kliff, Publisher, Diabetic Investor: Although it has taken much longer than I anticipated, market dynamics are forcing companies to think differently and we are now on the verge of patients being prescribed diabetes management systems rather than individual pieces of the system.
Read More »The Next CGMS is the Senseonics Eversence System
Once given FDA approval, the Senseonics Eversence System will be the fourth CGMS available in the U.S. It was submitted to the FDA for premarket approval last October, supported by data from a 90-patient pivotal trial of the device. The trial followed adults with type 1 or type 2 diabetes over 90 days of CGM sensor wearing. This is an implantable CGM system that is currently approved in Europe. The sensor sits just under your skin and can stay there for anywhere from 90-180 days.
Read More »Next CGMS “Flash” FreeStyle Libre FDA Approved, Available Shortly
CGM will be available at lower price, without fingerstick calibration, and can be worn for 10 days with 12-hour warmup.
Read More »Insulin Pump Interruptions Reduce Hypoglycemia
Sensor-augmented therapy can diminish hypoglycemia with the low-glucose suspend feature.
Read More »Abbott’s CGM Libre Approved by FDA
First Continuous Glucose Monitor that doesn’t require routine finger pricks.
Read More »Current Interview: Scott Abbott
Scott Abbott is the Director of Medical Development at Valeritas. He shares information from his presentation at the ADA on how the V-Go insulin delivery device can be used in the real world.
Read More »Scott Abbott Transcript
Dr. Scott Abbott discusses the V-Go wearable insulin delivery device, which is like a wearable insulin pen; it uses rapid-acting insulin and is approved as a pump-like device.
Read More »Scott Abbott Full Interview
In this Exclusive Interview, Scott Abbott talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about the use, benefits, and future of the V-Go insulin delivery system.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.